EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause

Kiyoshi Takamatsu iD, Takashi Miki, Kentaro Miyazaki, Atsuki Hashimoto, Antonia Morga, Xuegong Wang

Climacteric · 2026

DOI: 10.1080/13697137.2026.2664751 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Climacteric, 2026. Verfasst von Kiyoshi Takamatsu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tsukubamirai Endo Ladies Clinic, Tsukubamirai City, Japan. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 2-Ring, Hot Flashes, Menopause, Patient Reported Outcome Measures. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to report results of exploratory patient-reported outcomes (PROs) from the STARLIGHT study. METHOD: Perimenopausal/postmenopausal women aged ≥40 to ≤65 years from 36 centers in Japan seeking treatment/relief for vasomotor symptoms (VMS) associated with menopause were randomized 1:1:1, stratified by menopausal status, to receive fezolinetant 15 or 30 mg or placebo orally once daily for 12 weeks. The Patient-Reported Outcomes Measurement Information System Sleep Disturbance - Short Form 8b (PROMIS SD-SF 8b) total score, Menopause-Specific Quality of Life (MENQOL) total and domain scores, and Patient Global Impression of Change in Vasomotor Symptoms (PGI-C VMS) assessed the effect of fezolinetant on health-related quality of life (HRQoL). RESULTS: In total, 147 participants were randomized (placebo, n = 47; fezolinetant 15 mg, n = 53; fezolinetant 30 mg, n = 47). Improvements from baseline in the PROMIS SD-SF 8b total score and MENQOL total score were observed in the fezolinetant and placebo groups at weeks 4, 8 and 12. A higher proportion of participants in the fezolinetant 15 mg and fezolinetant 30 mg groups versus placebo reported improvement from baseline in the PGI-C VMS at weeks 4, 8 and 12. CONCLUSION: Fezolinetant was associated with improvements in PROs (PROMIS SD-SF-8b, MENQOL and PGI-C VMS); however, these analyses were exploratory and not powered for confirmatory hypothesis testing. Hot flashes and night sweats are common symptoms of menopause that can disrupt sleep and daily life. The STARLIGHT study was a phase II clinical trial to investigate whether a medicine, fezolinetant, could help women in Japan manage these symptoms and improve their quality of life. This manuscript reports the results of exploratory patient-reported outcomes (PROs) from the STARLIGHT study. In this study, 147 women aged between 40 and 65 years were randomly assigned to take either fezolinetant (15 mg or 30 mg) or a placebo (a pill with no active medicine) once a day for 12 weeks. Researchers asked participants about their sleep quality and menopause-related quality of life, and how they felt about their vasomotor symptoms (VMS).Women who took fezolinetant reported better sleep and felt their menopause symptoms had less impact on their lives compared to those who took placebo. These improvements were seen as early as 4 weeks and continued through 12 weeks.These findings suggest that fezolinetant may offer a new way to ease hot flashes and night sweats, helping women feel more comfortable and improving their quality of life during menopause.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 2-RingHot FlashesMenopausePatient Reported Outcome MeasuresQuinazolinesAdultAgedFemaleHumansMiddle AgedDouble-Blind MethodJapanQuality of LifeTreatment OutcomeThiadiazoles

Stichwörter der Autor:innen

FezolinetantJapanNCT05034042 (RCT2031210334)non-hormonal treatmentpatient-reported outcomesvasomotor symptoms

Substanzen

fezolinetantHeterocyclic Compounds, 2-RingQuinazolinesThiadiazoles

Autor:innen und Institutionen

  • Tsukubamirai Endo Ladies Clinic, Tsukubamirai City, Japan.
  • Astellas Pharma Inc., Tokyo, Japan.
  • Astellas Pharma Europe Ltd, Addlestone, UK.
  • Astellas Pharma Global Development, Northbrook, IL, USA.

ORCID-Profile: Kiyoshi Takamatsu

Förderung

  • Astellas Pharma Inc

Zitieren

APA

Takamatsu, K., Miki, T., Miyazaki, K., Hashimoto, A., Morga, A., & Wang, X. (2026). Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause. Climacteric. https://doi.org/10.1080/13697137.2026.2664751

Vancouver

Takamatsu K, Miki T, Miyazaki K, Hashimoto A, Morga A, Wang X. Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause. Climacteric. 2026. doi:10.1080/13697137.2026.2664751

BibTeX
@article{Takamatsu2026,
  author = {Takamatsu, Kiyoshi and Miki, Takashi and Miyazaki, Kentaro and Hashimoto, Atsuki and Morga, Antonia and Wang, Xuegong},
  title = {Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopause},
  journal = {Climacteric},
  year = {2026},
  doi = {10.1080/13697137.2026.2664751}
}
Kostenlos starten →